These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 10427537)

  • 1. [A survey of clinically used drugs in PVR: a review].
    Faude F; Heimann K; Wiedemann P
    Klin Monbl Augenheilkd; 1999 Jun; 214(6):362-6. PubMed ID: 10427537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy.
    Charteris DG; Aylward GW; Wong D; Groenewald C; Asaria RH; Bunce C;
    Ophthalmology; 2004 Dec; 111(12):2240-5. PubMed ID: 15582080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacological adjuvants for surgical treatment of proliferative vitreoretinopathy].
    Scheer S; Morel C; Touzeau O; Sahel JA; Laroche L
    J Fr Ophtalmol; 2004 Nov; 27(9 Pt 1):1051-9. PubMed ID: 15557870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy.
    Ozerdem U; Mach-Hofacre B; Cheng L; Chaidhawangul S; Keefe K; McDermott CD; Bergeron-Lynn G; Appelt K; Freeman WR
    Curr Eye Res; 2000 Jun; 20(6):447-53. PubMed ID: 10980656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy.
    Berger AS; Cheng CK; Pearson PA; Ashton P; Crooks PA; Cynkowski T; Cynkowska G; Jaffe GJ
    Invest Ophthalmol Vis Sci; 1996 Oct; 37(11):2318-25. PubMed ID: 8843916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy: a randomized clinical trial.
    Ahmadieh H; Feghhi M; Tabatabaei H; Shoeibi N; Ramezani A; Mohebbi MR
    Ophthalmology; 2008 Nov; 115(11):1938-43. PubMed ID: 18584876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal daunomycin induces multidrug resistance in proliferative vitreoretinopathy.
    Esser P; Tervooren D; Heimann K; Kociok N; Bartz-Schmidt KU; Walter P; Weller M
    Invest Ophthalmol Vis Sci; 1998 Jan; 39(1):164-70. PubMed ID: 9430558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antiproliferative effect of sustained drug delivery system of all-trans retinoic acid implant into rabbit's vitreous cavity for treatment of proliferative vitreoretinopathy].
    Yan XR; Dong XG; Chen N; Wang W
    Zhonghua Yan Ke Za Zhi; 2003 Oct; 39(10):621-5. PubMed ID: 14766078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribozyme to proliferating cell nuclear antigen to treat proliferative vitreoretinopathy.
    Mandava N; Blackburn P; Paul DB; Wilson MW; Read SB; Alspaugh E; Tritz R; Barber JR; Robbins JM; Kruse CA
    Invest Ophthalmol Vis Sci; 2002 Oct; 43(10):3338-48. PubMed ID: 12356843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of 5-fluorouracil polyactic acid microsphere in prevention of proliferative vitreoretinopathy].
    Bi HS; Cui Y; Zhang JH; Wang XR; Xie XF
    Zhonghua Yan Ke Za Zhi; 2006 Jan; 42(1):37-41. PubMed ID: 16638279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized controlled trial of combined 5-Fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy.
    Wickham L; Bunce C; Wong D; McGurn D; Charteris DG
    Ophthalmology; 2007 Apr; 114(4):698-704. PubMed ID: 17398320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of oral 13-cis-retinoic acid treatment on postoperative clinical outcome of eyes with proliferative vitreoretinopathy.
    Chang YC; Hu DN; Wu WC
    Am J Ophthalmol; 2008 Sep; 146(3):440-446. PubMed ID: 18599016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study.
    Kon CH; Occleston NL; Aylward GW; Khaw PT
    Invest Ophthalmol Vis Sci; 1999 Mar; 40(3):705-12. PubMed ID: 10067974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of genistin on proliferative vitreoretinopathy].
    You J; Jiang D
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Jul; 35(7):749-53. PubMed ID: 20693719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical risk factors for postoperative proliferative vitreoretinopathy (PVR). A prospective study].
    Rodríguez de la Rúa E; Martínez V; Aragón J; Sanabria RM; Giraldo A; Mayo A; Pastor JC; Miranda I; García Arumí J
    Arch Soc Esp Oftalmol; 2003 Feb; 78(2):91-7. PubMed ID: 12647249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New drugs with novel therapeutic characteristics. Have they been subject to randomized controlled trials?
    Lexchin J
    Can Fam Physician; 2002 Sep; 48():1487-92. PubMed ID: 12371307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained release of cis-hydroxyproline in the treatment of experimental proliferative vitreoretinopathy in rabbits.
    Yasukawa T; Kimura H; Tabata Y; Miyamoto H; Honda Y; Ogura Y
    Graefes Arch Clin Exp Ophthalmol; 2002 Aug; 240(8):672-8. PubMed ID: 12192462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new model of proliferative vitreoretinopathy.
    Frenzel EM; Neely KA; Walsh AW; Cameron JD; Gregerson DS
    Invest Ophthalmol Vis Sci; 1998 Oct; 39(11):2157-64. PubMed ID: 9761295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proliferative vitreoretinopathy: does oral low-dose colchicine have an inhibitory effect? A controlled study in humans.
    Berman DH; Gombos GM
    Ophthalmic Surg; 1989 Apr; 20(4):268-72. PubMed ID: 2733993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective study of matrix metalloproteinases in proliferative vitreoretinopathy.
    Kon CH; Occleston NL; Charteris D; Daniels J; Aylward GW; Khaw PT
    Invest Ophthalmol Vis Sci; 1998 Jul; 39(8):1524-9. PubMed ID: 9660504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.